Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : EntreMed (ENMD) -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (439)	5/3/1998 10:33:00 PM
From: muddphudd	Read Replies (1) \| Respond to of 2135

I experienced the same thing except, as a neophyte investor, I bought ENMD when I heard the news about the NATURE paper. I got it at $14.5. As you mentioned, it subsequently pulled back to the $12 level. Rookie mistake. Nonetheless, I like the scientific principals and medical implications. I saw lots of surgeries in med school; tumors bleed significantly upon resection. Folkmans' work clearly supports the notion that this 'surgical bleeding' is due to the extensive vascularization of tumors. The potential benefit of anti-angiogenesis to cancer patients is astounding. This is truly the hottest promising thing cancer medicine has seen in a long time. However, I too believe that the coverage we have seen this weekend will only result in a short-term run in the stock price. Clinical-trial news is the only thing that could permanently move the price up.